VolitionRx Limited

Back to All Transactions

VolitionRx Limited
For more information regarding this transaction contact:
  • Mike Townley Investment Banking 213.536.0241
  • Dave McDonald Investment Banking 612.326.1268
  • Rob Martin Investment Banking 612.260.5850

VolitionRx Limited

Lake Street Capital Markets is pleased to announce it served as a joint book-running manager for VolitionRx Limited (NYSE MKT: VNRX), a blood-based cancer diagnostics company, in its public offering of 2,846,250 shares of common stock at a price of $3.75 per share.  Gross proceeds totaled $10.7 million.  Concurrent with the closing of the offering the company uplisted to the NYSE MKT exchange.

About VolitionRx

VolitionRx is a clinical stage life sciences company focused on developing blood-based diagnostic tests that meet the need for accurate, fast, inexpensive and scalable tests for detecting and diagnosing cancer and other diseases.  The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests.  VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.


Mike Townley
Head of Investment Banking


Email Mike

Dave McDonald
Head of Life Science Investment Banking


Email Dave


Tim Klein

Investment Banking


Email Tim


Rob Martin

Investment Banking


Email Rob


Steve Rickman

Investment Banking


Email Steve